[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 5 sources · 5 days · First seen · Last updated

Oruka Therapeutics drug development expansion

Overview

Oruka Therapeutics has expanded the development rights for its lead IL-23 program, ORKA-001, to include inflammatory bowel disease (IBD) following an amended license agreement with Paragon Therapeutics. The company is currently conducting Phase 2b trials for moderate-to-severe plaque psoriasis, with a Phase 3 program scheduled for the first half of 2027.

Management expects its $1.1 billion cash position to fund operations through the anticipated Biologics License Application filing for ORKA-001. Additionally, the company is advancing ORKA-004, a monoclonal antibody targeting TL1A, which is projected to enter clinical development in late 2026.

Entities

Oruka Therapeutics · Sumitomo Mitsui Financial Group · Brian Charles Shackley · Lawrence Klein · AeroVironment, Inc.

Timeline

  1. 2 days ago

    [BUSINESS] 2 sources
    Oracle and Sumitomo Mitsui see notable stock transactions

    Leeward Financial Partners LLC invested $898,000 in Oracle Corporation, while Sumitomo Mitsui Financial Group CFO Kazuyuki Anchi sold 4,000 shares of company stock.

  2. 7 days ago

    [BUSINESS] 4 sources
    Oruka Therapeutics expands drug development into inflammatory bowel disease

    Oruka Therapeutics is expanding its ORKA-001 program into inflammatory bowel disease, supported by a $1.1 billion cash position and recent stock price highs.

Sources

cryptobriefing.com · mommygearest.com · otravel.com · pulse2.com · stocknews.com